Adempas (riociguat)

05:38 EST 16th December 2018 | BioPortfolio

The United States Food and Drug Administration (FDA) has approved on October 8th 2013 Adempas® (riociguat) tablets for:
(i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and
(ii) the treatment of adults with pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.

PAH is a disease characterized by elevated pressure in the pulmonary arteries.  CTEPH is a form of pulmonary hypertension in which blood clots and thromboembolic occlusion of the pulmonary vessels leads to increased pressure in the pulmonary arteries.  The standard treatment for CTEPH is pulmonary endarterectomy, a potentially curative surgery that clears clots and scar material from the blood vessels of the lung.

Adempas, a stimulator of soluable guanylate cyclase (sGC), represents a new class of drug now available in the U.S.  Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of nitric oxide (NO) and insufficient stimulation of the NO-sGC-cGMP pathway.  Adempas sensitizes sGC to endogenous NO by stabilizing the NO-sGC binding.  Adempas also directly stimulates sGC via a different binding site independently of NO.  Adempas restores the NO-sGC-cGMP pathway and leads to increased generation of cGMP with subsequent vasodialation.

Quick Search


review and buy Adempas (riociguat) market research data and corporate reports here